Zila tries again with new oral cancer test protocol
This article was originally published in Clinica
Executive Summary
Zila has submitted a new protocol for an additional clinical study of its oral cancer test to the US FDA. Data from the new study will be used to amend the company's previous drug application for the OraTest oral rinse, which failed to win backing from an FDA panel earlier this year (see Clinica 842, p 13).